Author

Andrea Cuconati

Arbutus Biopharma, Inc. - Cited by 4,770 - Antiviral drug discovery - virus-host cell interactions - viral replication

Biography

Dr.Andrea Cuconati is currently working at Institute for Hepatitis and Virus Research, The Hepatitis B Foundation, Pennsylvania Biotechnology Center, Doylestown, PA 18902, USA. His research interest includes such as Drug Discovery, Medicinal and Pharmaceutical Chemistry, Molecular Virology, Immunology of Infectious Diseases, Emerging Infectious Diseases, viral immunology, viral infection, cell culture. His has done totally 85 publications in his field of research.
Title
Cited by
Year
Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein
R Mao, H Nie, D Cai, J Zhang, H Liu, R Yan, A Cuconati, TM Block, ...PLoS pathogens 9 (7), e1003494, 2013201
221
2013
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43
X Zhao, F Guo, F Liu, A Cuconati, J Chang, TM Block, JT GuoProceedings of the National Academy of Sciences 111 (18), 6756-6761, 2014201
171
2014
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids
MR Campagna, F Liu, R Mao, C Mills, D Cai, F Guo, X Zhao, H Ye, ...Journal of virology 87 (12), 6931-6942, 2013201
169
2013
HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways
F Guo, Q Zhao, M Sheraz, J Cheng, Y Qi, Q Su, A Cuconati, L Wei, Y Du, ...PLoS pathogens 13 (9), e1006658, 2017201
111
2017
Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses
J Chang, TK Warren, X Zhao, T Gill, F Guo, L Wang, MA Comunale, Y Du, ...Antiviral research 98 (3), 432-440, 2013201
85
2013
Spinoculation enhances HBV infection in NTCP-reconstituted hepatocytes
R Yan, Y Zhang, D Cai, Y Liu, A Cuconati, H GuoPloS one 10 (6), e0129889, 2015201
76
2015
Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by …
X Zhao, F Guo, MA Comunale, A Mehta, M Sehgal, P Jain, A Cuconati, ...Antimicrobial agents and chemotherapy 59 (1), 206-216, 2015201
66
2015
Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by …
X Zhao, F Guo, MA Comunale, A Mehta, M Sehgal, P Jain, A Cuconati, ...Antimicrobial agents and chemotherapy 59 (1), 206-216, 2015201
66
2015
Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators
D Cai, X Wang, R Yan, R Mao, Y Liu, C Ji, A Cuconati, H GuoAntiviral research 132, 26-37, 2016201
55
2016
Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA encapsidation
N Mani, AG Cole, JR Phelps, A Ardzinski, KD Cobarrubias, A Cuconati, ...Antimicrobial agents and chemotherapy 62 (6), 10.1128/aac. 00082-18, 2018201
50
2018
Inhibitors of secretion of hepatitis B virus antigens
X Xu, A Cuconati, TM Block, T XiaoUS Patent 8,921,381, 2014201
43
2014
Substituted triazolo [1, 5-A] pyrimidines as antiviral agents
A Cuconati, TM Block, X XuUS Patent 8,609,668, 2013201
40
2013
ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection
EP Thi, AP Dhillon, A Ardzinski, L Bidirici-Ertekin, KD Cobarrubias, ...ACS Infectious Diseases 5 (5), 725-737, 2018201
38
2018
A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein
F Guo, S Wu, J Julander, J Ma, X Zhang, J Kulp, A Cuconati, TM Block, ...Journal of Virology 90 (23), 10774-10788, 2016201
35
2016
An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses
F Guo, X Zhao, T Gill, Y Zhou, M Campagna, L Wang, F Liu, P Zhang, ...Antiviral research 107, 56-65, 2014201
15
2014
The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies
N Mani, AG Cole, A Ardzinski, D Cai, A Cuconati, BD Dorsey, F Guo, ...Hepatology 63 (1 SUPP), 123A-124A, 2016201
13
2016
FRI-184-Function and drug combination studies in cell culture models for AB-729, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infection
FRI-184-Function and drug combination studies in cell culture models for AB-72, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infectionACH Lee, EP Thi, A Cuconati, A Ardzinski, R Holland, H Huang, ...Journal of Hepatology 70 (1), e471, 20120
9
2019
Exploring combination therapy for curing HBV: preclinical studies with capsid inhibitor AB-423 and a siRNA agent, ARB-1740
AC Lee, AP Dhillon, SP Reid, EP Thi, JR Phelps, K McClintock, AH Li, ...Hepatology 63 (1 SUPP), 122A-123A, 2016201
9
2016
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein
N Mani, AG Cole, JR Phelps, A Ardzinski, R Burns, T Chiu, A Cuconati, ...Antiviral Research 17, 105211, 2022202
9
2022
Hepatitis B Virus
H Guo, A CuconatiSpringer New York, 2017201
8
2017

Referred From: https://scholar.google.com/citations?user=bPn1HnwAAAAJ&hl=en

Cited by
Citations 4770
h-index 35
i10-index 45
Recommended Journals
Open Access Journals